Magnolo N, Kingo K, Laquer V, et al. - In pediatric patients with moderate-to-severe plaque psoriasis, secukinumab dosing regimens were both effective and well-tolerated.

• It was a Phase-III, open-label, randomized, multicenter-study.

• At Week-12, both secukinumab doses (low dose: 75/75/150 mg and high dose: 75/150/300 mg) outperformed the historical placebo in terms of PASI 75/90 and IGA0/1 responses.

• The estimated probability of a positive treatment effect (ie, log-Odd Ratio [OR] > 0) for secukinumab low or high dose vs historical placebo is 1 (ie, 100%).

• At Week-12, the IGA0/1 response rates were 78.6% and 83.3%, respectively, and the PASI90 response rates were 69% and 76.2%, respectively; the PASI75 response rate was 92.9% for both dosages.